Clinical Trial Update: A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating mavrilimumab versus anti-TNF therapy in rheumatoid arthritis completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Mavrilimumab (mavrilimumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2016-10-31